Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA approves AbbVie’s Rinvoq for nr-axSpA

By Brian Buntz | October 21, 2022

AbbVieFDA has approved AbbVie’s Rinvoq (upadacitinib) for adults with active non-radiographic axial spondyloarthritis (nr-axSpA). 

The indication covers nr-axSpA patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors. 

The JAK1 selective inhibitor Rinvoq now has six U.S. indications. 

The new indication makes Rinvoq the only JAK inhibitor approved for adults with nr-axSpA.

RinvoqTo win the latest indication, Abbott submitted data from the Phase 3 SELECT-AXIS 2 clinical study focusing on adults with active nr-axSpA. The placebo-controlled study found that almost half of the recipients of Rinvoq 15 mg had achieved at least 40% improvement based on the Assessment in SpondyloArthritis International Society scale (ASAS40) at week 14. ASAS40 was the primary endpoint. 

The safety profile of Rinvoq was similar in the nr-axSpA demographic to earlier Rinvoq trials involving patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

FDA first approved Rinvoq for moderate to severe rheumatoid arthritis in 2019. An indication followed for active psoriatic arthritis in 2021.

FDA granted three additional indications to Rinvoq in the first half of 2022 — for atopic dermatitis, ulcerative colitis and active ankylosing spondylitis.

In July, North Chicago, Illinois–based Abbott announced that it is also pursuing a Rinvoq indication for Crohn’s disease. 

Nr-axSpA is a chronic inflammatory disease associated with joint inflammation. X-ray cannot detect Nr-axSpA. 

The company is also pursuing Rinvoq indications for giant cell arteritis and Takayasu arteritis. 

AbbVie hopes Rinvoq’s growing use will help reduce its reliance on Humira, which drove almost 37% of its revenue in 2021. 

In 2021, FDA released a safety communication about JAK inhibitors, warning about their potential to cause cardiovascular side effects. The warning focused on Pfizer’s Xeljanz (tofacitinib), which was studied in the ORAL Surveillance study, which was profiled in NEJM. The FDA’s notice acknowledged that it did not have sufficient data to adequately evaluate Rinvoq but noted that the medication “may have similar risks as seen in the Xeljanz safety trial.”

The decision added “black box warnings” to all FDA-approved JAK inhibitors for inflammatory diseases. 


Filed Under: Rheumatology
Tagged With: nr-axSpA, Rinvoq
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Rosnilimab phase 2b trial shows promise in treating RA
rosnilimab
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance 
Zai Lab
Zai Lab’s unified approach to tackling cancer, autoimmune, and neurological diseases
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE